Antonia D Aniello

Dr. Antonia D Aniello


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Chemistry – A European Journal
Verified
Journal Article
Open access
Concetta AvitabileConcetta Avitabile
Concetta Avitabile
MCMaria Teresa Cerasa
Maria Teresa Cerasa
AAAntonia D Aniello
Antonia D Aniello
MSMichele Saviano
Michele Saviano
Maria MocciaMaria Moccia
Maria Moccia
Peptide nucleic acids (PNAs) have garnered significant attention due to their enhanced chemical, physical, and binding properties in comparison to natural nucleic acids. This prompted their application in antigene/antisense approach, assigning them a pivotal role in gene editing and, more recently, showing their potential as “bilingual” molecules being able “to speak” both nucleic acid and protein language. However, to expand the applications of PNAs in therapy, the challenge of effectively delivering PNAs to cells needs to be addressed. Among several delivery approaches employed so far, the nanotechnology‐based ones showed great potential. In this review, we provide an overview of the latest in the field (2019 to present), beginning from peptide‐based delivery systems, as well as cutting‐edge approaches involving nanoparticles, liposomes, and calixarene, showing how they have inspired the development of smarter delivery approaches to boost PNAs applications.

Verified
Journal Article
Open access
PDF file
AAAntonia D Aniello
Antonia D Aniello
Annalisa MasiAnnalisa Masi
Annalisa Masi
Concetta AvitabileConcetta Avitabile
Concetta Avitabile
GMGiovanni del Monaco
Giovanni del Monaco
MSMichele Saviano
Michele Saviano
Maria MocciaMaria Moccia
Maria Moccia
The global rise in antimicrobial resistance (AMR) demands innovative strategies beyond traditional antibiotics. Peptide Nucleic Acids (PNAs), synthetic DNA analogues with peptide-like backbones, act as thermically, chemically, and enzymatically stable sequence-specific agents capable of silencing essential bacterial genes. Through antisense mechanisms, PNAs bind bacterial mRNA or rRNA, blocking translation or ribosome assembly and thereby inducing species-specific growth inhibition. Their programmable design enables precise targeting of multidrug-resistant pathogens while sparing commensal microbiota. Recent advances, including γ-modified backbones, cationic substitutions, and delivery platforms such as cell-penetrating peptides (CPPs), dendron conjugates, and nanoparticles, have improved solubility, stability, and cellular uptake. Studies show promising in vitro and, albeit less frequently, in vivo efficacy against both Gram-positive and Gram-negative bacteria, often with synergistic activity when combined with conventional antibiotics. Although challenges remain in delivery and large-scale production, PNAs represent a promising class of antimicrobials to combat AMR through targeted gene inhibition.